






































In 2000, Franceschi et al. [1] coined the term 
"inflammaging" in order to refer to a low-grade pro-
inflammatory status appearing during the aging process. 
They emphasized the role of macrophages as well as 
cellular stress and genetic factors in the generation of 
the inflammaging condition. In addition, they 
hypothesized that this inflammatory environment could 
predispose the organism to the development of several 
age-related diseases. During recent years, this scenario 
has been confirmed by a plethora of experimental 
evidence. However, it seems that concurrently with the 
chronic, low-level inflammation one encounters several 
symptoms of immunosenescence, both in the innate and  
 
 





































adaptive immune systems [2,3]. The presence of a pro-
inflammatory phenotype in aged mammals is evident by 
(i) increased expression of genes linked to inflammation 
and immune responses in the tissues of old humans and 
rodents [4-6], (ii) higher level of cytokines in serum, 
e.g. IL-6 and TNF-α [7,8], (iii) activation of NF-κB 
signaling which is the master regulator of inflammatory 
responses [9-11]. There are tissue specific differences in 
the production of age-related inflammatory factors as 
well as in the onset and level of pathological changes 
[12].  
 
It is known that systemic inflammation linked to 
inflammaging aggravates e.g. the vascular pathology 
and provokes atherosclerosis  [4].  Moreover,  increased  





























diseases,  e.g. atherosclerosis,  obesity  and  type 2 diabetes.  NLRP3  activates  inflammatory  caspases, mostly  caspase‐1,
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pituitary-adrenal (HPA) axis which augments the 
secretion of cortisol [13]. Cortisol is a potent anti-
inflammatory agent although it not only induces protein 
catabolism, e.g. in muscle tissues, but it also promotes 
bone resorption. Chronic inflammation can also 
enhance the appearance of insulin resistance in muscles 
and adipose tissues as well as disturb the maintenance 
of energy homeostasis and subsequently cellular 
housekeeping functions. Interestingly, the aging process 
is simultaneously accompanied by both the features 
accelerating inflammaging and the counteracting, so-
called anti-inflammaging characteristics [14]. It seems 
that the balance between these opposite forces controls 
the outcome of the aging process, either leading to 
frailty and degenerative diseases or a healthy old age 
and longevity.   
 
Inflammasomes: molecular platforms for danger 
signal recognition  
 
The aging process jeopardizes the maintenance of 
cellular homeostasis leading to the activation of a 
variety of host defence systems. Inflammasomes are 
intracellular multiprotein sensors which can recognize a 
large set of danger signals, induced either by pathogens 
or cellular stress, and once activated, they subsequently 
stimulate inflammatory responses [15-18]. There are 
several subfamilies of NOD-like receptors (NLR) but 
emerging data indicates that the NLRP subfamily, in 
particular the NLRP3 member, is the major sensor for 
"intracellular danger-associated molecular patterns" 
(DAMPs). Inflammasomes are signaling platforms 
which are assembled after the recognition of DAMP by 
the receptor protein. In the case of NLRP3, the activated 
receptor interacts with the adaptor protein ASC which 
recruits the inflammatory caspase-1 (CASP-1) to the 
complex which subsequently oligomerizes into penta- 
or heptameric inflammasomes [16,19]. CASP-1 is the 
common effector molecule in inflammasomes which 
cleaves the inactive precursors of two proinflammatory 
cytokines, i.e. IL-1β and IL-18, into their mature forms 
which are then secreted from cells. In addition to 
CASP-1, some other inflammatory caspases, e.g. 
CASP-4, CASP-5 and CASP-12, can also process the 
proforms of these cytokine [16,20]. In general, the 
expression levels of NLRP3 receptor as well as the 
precursors of IL-1β and IL-18 remain low and 
activation of NLRP3 inflammasomes requires a priming 
phase while the expression of these proteins is clearly 
induced [17,21,22]. Interestingly, NF-κB signaling is a 
crucial inducer of NLRP3 expression [21]. It should be 
noted that different cellular stresses and the aging 
process can stimulate NF-κB signaling [11,23] and 
probably enhance the priming and potentiation of the 
inflammasome activation. 
 
Infections and tissue injuries can trigger an 
inflammatory reaction as a physiological host defence 
mechanism but in addition, cellular stress can also alert 
the immune system and induce adaptive responses. This 
kind of inflammation was termed "para-inflammation" 
by Medzhitov [24]. Recent studies have revealed that 
NLRP3 is the major receptor for endogenous danger 
insults to facilitate inflammatory responses. Petrilli et 
al. [25] demonstrated that the efflux of potassium, an 
effect evoked by many noxious stimuli, could activate 
NLRP3 inflammasomes. After this initial observation, 
several different activation mechanisms have been 
identified but still there is an ongoing debate about 
whether they are physiological inducers and what kind 
of responses they stimulate. The increased level of 
reactive oxygen species (ROS) induced by oxidative 
stress was one of the first stimuli which was 
demonstrated to trigger NLRP3 activation and promote 
CASP-1 -dependent IL-1β secretion [26,27]. 
Furthermore, several studies have indicated that the 
release of cathepsin B after lysosomal damage can 
activate NLRP3 [28,29]. Lysosomal destabilization is 
also associated with the NLRP3 activation induced by 
cholesterol crystals in macrophages [30], probably 
involved in the inflammation promoting atherosclerosis. 
There are some observations that amyloid fibrils, e.g. 
islet amyloid polypeptides (IAPP) and Alzheimer's 
amyloid-β, can trigger NLRP3 inflammasomes [28,31] 
and in that way stimulate inflammation and enhance 
pathogenesis in type 2 diabetes and Alzheimer's disease, 
respectively.  
 
Recently, Wen et al. [32] demonstrated in macrophages 
that palmitate, a saturated fatty acid, could activate 
NLRP3 whereas the unsaturated oleate was not 
responsive. Interestingly, NLRP3 activation was ROS-
dependent and secreted IL-1β impaired insulin signaling 
and promoted insulin resistance in mice. Vandanmagsar 
et al. [33] revealed that obesity was associated with the 
activation of NLRP3 in adipose tissue. These workers 
observed that the weight loss of obese humans, induced 
by caloric restriction and exercise, was associated with 
(i) a reduction of NLRP3 expression in adipose tissue, 
(ii) a decrease in the level of inflammation and (iii) an 
increase in insulin sensitivity. Supporting these results, 
Stienstra et al. [34] observed that transgenic mice which 
lack Nlrp3, Asc and caspase-1 genes were resistant to 
the obesity induced by high-fat diet and protected from 
insulin resistance. It seems that NLRP3 could be a 
sensor for metabolic stress recognizing ROS production 
[35]. Tschopp and Schroder [36] speculated that 
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NLRP3 inflammasomes via ROS production.   
 
Recently, Zhou et al. [37] demonstrated that 
mitochondria were crucially involved in the activation 
of NLRP3. They observed that increased mitochondrial 
production of ROS stimulated NLRP3 whereas the 
inhibition of ROS production, either with an enhanced 
autophagic uptake of damaged mitochondria or by 
inhibiting the expression of voltage-dependent anion 
channels (VDAC2), significantly suppressed the 
stimulation of NLRP3. Their study emphasized the 
significant role of mitochondria and in particular, their 
proper clearance by autophagy in the regulation of 
NLRP3 activation. Autophagy was also shown to be a 
fundamental host defence mechanism against invading 
intracellular microbes [38]. Moreover, deficiency in 
autophagy, e.g. in Crohn's disease, triggers 
inflammatory responses and leads to tissue injuries [39]. 
It seems plausible that autophagy, a guardian of cellular 
sanctity, is a potent anti-inflammatory mechanism 
which controls the activation of danger sensors, i.e. 

































Autophagy: master of housekeeping prevents 
inflammasome activation  
 
Autophagy is an ancient housekeeping mechanism 
which controls the cellular homeostasis by facilitating 
the removal of misfolded proteins and dysfunctional 
organelles, e.g. mitochondria and endoplasmic 
reticulum, for degradation in lysosomal system [39,40]. 
There are three pathways which can deliver cytoplasmic 
material for autophagic degradation, i.e. macro- and 
microautophagy as well as chaperone-mediated 
autophagy. Macroautophagy, segregating organelles 
like mitochondria, is the major type of autophagy 
associated with innate immunity [41,42] and it is 
hereafter shortly called "autophagy". In addition to the 
cleansing function, autophagy can regulate cellular 
energy balance, e.g. during starvation it can trigger 
energy production from its own components [43]. 
Autophagy may also be involved in lipid metabolism by 
sequestering lipid droplets [44]. In conjunction with this 
increased knowledge on inflammasomes, the role of 
autophagy in the regulation of inflammatory responses 
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suppress inflammatory reactions [42,45-47]. For instance, 
loss of autophagy proteins, e.g. Atg16L1, potentiates 
endotoxin-induced IL-1β production [48]. Moreover, 
genetic studies have revealed that two autophagy genes, 
Atg16L1 and IRGM are associated with the pathogenesis 
of Crohn's disease, an inflammatory bowel disease [39]. 
It is known that autophagy regulates the inflammatory 
reaction, e.g. in adipocytes [49] and keratinocytes [50]. 
Meng and Cai [51] demonstrated that defective 
autophagy in hypothalamus induced inflammation and 
subsequently led to obesity and insulin resistance when 
mice were fed a high-fat diet. Interestingly, these workers 
observed that the effects of reduced autophagy were 
reversed by the inhibition of inhibitory-κB kinase β 
(IKKβ) indicating that inflammation was induced by NF-
κB signaling. On the other hand, potentiation of 
autophagy, e.g. by inhibitors of mammalian target of 
rapamycin (mTOR) and activators of AMP-activated 
protein kinase (AMPK), can reduce inflammation and 
tissue pathology in several diseases [39,45,52] (see also 
below). Shi et al. [53] demonstrated in human 
macrophages that increasing the autophagy by starvation 
and rapamycin treatment reduced CASP-1 activity and 
secretion of IL-1β whereas blocking the autophagy 
clearly enhanced inflammasome activity. They also 
observed that autophagic adaptor protein, 
p62/sequestosome-1, delivered ubiquitinated inflamma-
somes to degradation in autophagosomes. 
 
Mitochondria have a crucial role in the regulation of 
innate immunity responses [54,55]. In addition to the 
ROS-dependent activation of NLRP3 inflammasomes, 
mitochondria (i) are involved in the control of antiviral 
RIG-1-like receptor (RLR) signaling pathways, (ii) 
contain NLRX1 receptors which monitor e.g. ROS 
production, and (iii) secrete several DAMPs, such as 
ROS, mitochondrial DNA (mtDNA) and formyl 
peptides [54,56]. The studies by Zhou et al. [37] and 
Nakahira et al. [57] clearly demonstrated that secretion 
of ROS and mtDNA from mitochondria activated 
inflammasomes, i.e. mitochondria with disrupted 
integrity and impaired autophagic clearance are the 
crucial regulators of inflammasomal activation and 
subsequently inflammatory responses. Nakahira et al. 
[57] revealed that depletion of autophagic proteins 
impaired mitochondrial integrity and increased their 
ROS production. They also demonstrated that ROS 
were required for caspase-1 activation, a prerequisite for 
the maturation of IL-1β and IL-18. They also observed 
that NLRP3 mediates the release of mtDNA which 
seems to function as a co-activator of caspase-1. In 
contrast, Zhou et al. [27] reported that ROS could 
dissociate the complex between thioredoxin (TRX) and 
thioredoxin-interacting protein (TXNIP), and 
consequently TXNIP activated NLRP3. Xiang et al. 
[58] demonstrated in endothelial cells that ROS 
produced by NADPH oxidase stimulated the release of 
TXNIP and its binding to NLRP3 and subsequently 
induced IL-1β secretion. There is also the possibility 
that ROS could directly oxidize thiol groups in leucine-
rich repeat (LRR) domain of NLRP3 and in that way 
activate the inflammasomal pathway [17]. Interestingly, 
there are several studies which demonstrate that ROS 
can activate autophagy and thus enhance the autophagic 
cleansing of dysfunctional mitochondria or misfolded 
proteins [59] and in that way reduce the activation of 
inflammasomes and the risk for tissue injuries.    
 
In conclusion, all these observations emphasize that a 
deficiency in the cellular housekeeping can trigger the 
inflammatory danger sensor NLRP3, and also NLRP1 
in some tissues like brain [60], and by this means 
stimulate inflammatory reactions in sensitive tissues. In 
this respect, the effective function of autophagic uptake 
and lysosomal degradation of dysfunctional 
mitochondria and aggregated proteins is a crucial 
element in maintaining tissue homeostasis. There are 
indications that autophagic capacity is compromised in 
certain diseases [61,62], e.g. in Alzheimer's disease 
[63]. On the other hand, there is growing evidence 
implying that inflammasomes are activated in many 
pathological conditions [64,65] and thus a deficiency in 
autophagic housekeeping could trigger an inflammatory 
component and aggravate their pathogenesis.  
 
Autophagy declines with aging enhancing the 
inflammaging process 
 
The aging process involves a progressive decline in 
cellular and organismal function. The major hallmark of 
aging is the deficient maintenance of proteostasis which 
permits the accumulation of damaged and defective 
cellular components, e.g. lipofuscin, within cells. Brunk 
and Terman [66] called this cellular status as "garbage 
can" hypothesis of aging. They proposed that lipofuscin 
accumulation would disturb lysosomal degradation thus 
inhibiting the cleansing of dysfunctional mitochondria. 
After ten years of experimental work, this hypothesis 
still seems to be valid since different research 
approaches have demonstrated that autophagy clearly 
declines with aging and the number of dysfunctional 
mitochondria augments. In particular, defects in 
mitochondrial uptake and degradation could increase 
ROS production and stimulate inflammasomes. 
Recently, this research topic has been extensively 
reviewed in detail elsewhere [67-72]. 
 
Many studies have indicated that the inhibition of 
autophagy by genetic manipulation provokes age-
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many organisms, e.g. C. elegans, Drosophila and mice 
[71,73,74]. Wu et al. [75] demonstrated that the deletion 
of the Atg7 gene induced mitochondrial disturbances, 
e.g. increased production of ROS and alterations in the 
metabolic profile, in mouse skeletal muscle. Cuervo and 
Dice [76] observed that also chaperone-mediated 
autophagy (CMA), not only macroautophagy, was 
impaired in rat liver during aging. They revealed that 
the decline was caused by an age-related decrease in the 
expression of LAMP-2A, the receptor protein of CMA. 
Interestingly, in subsequent studies [77], they 
demonstrated that the prevention of the age-related loss 
of LAMP-2A protein in transgenic mice could maintain 
efficient CMA and that this was associated with a 
reduction in the level of damaged proteins and 
improved liver function during aging. Many studies 
have also demonstrated that increasing the autophagic 
capacity by pharmacological or genetical manipulations 
can prevent the pathology linked to the aging process 
and even extend lifespan [78-80]. For instance, 
pharmacological induction of autophagy, e.g. by 
inhibiting mTOR by rapamycin can increase the 
lifespan of mice [79] (see below). 
 
Caloric restriction (CR) is the most common anti-aging 
intervention which can extend lifespan in organisms 
ranging from yeast to humans [81]. CR is a potent 
physiological activator of autophagy [82,83]. Several 
studies have demonstrated that autophagy is required 
for the CR-mediated lifespan extension [71,83]. Colman 
et al. [84] revealed that CR delayed the onset of many 
age-related pathologies, e.g. incidence of diabetes, 
cancer, cardiovascular disease and brain atrophy, as 
well as reducing the mortality of rhesus monkeys. 
Moreover, it is known that CR effectively protects 
against inflammatory responses and can combat age-
related pro-inflammatory phenotype [85,86]. CR has 
also several beneficial effects on mitochondrial quality 
control, e.g. ROS production [87,88], which can 
improve cellular housekeeping and prevent 
inflammasomal activation. Many studies have indicated 
that mitochondrial quality control has a key role in the 
regulation of the aging process [89,90]. For instance, 
Trifunovic et al. [91] demonstrated that triggering of 
point mutations and deletions into mtDNA induced a 
premature aging phenotype in mice.  
 
There are several regulatory mechanisms which could 
augment the appearance of inflammaging phenotype 
during the age-related deficiency of autophagy. It is 
well-known that increased levels of ROS can activate 
NF-κB signaling via multiple mechanisms [92-94]. For 
instance, several redox-sensitive protein kinases and 
phosphatases can stimulate IKK-NF-κB signaling and 
thus induce and maintain an elevated priming state of 
inflammasomal system. Moreover, a decline in 
autophagy can stimulate the activating kinases of the 
NF-κB complex, i.e. IκB kinase α and β (IKKα/β) and 
NF-κB-inducing kinase (NIK), which are degraded via 
selective autophagy [95-97]. Sequestosome-1/p62 is a 
cargo receptor for selective autophagy [98] and changes 
in autophagy regulate the p62 level which controls the 
formation of protein aggregates as well as activation of 
NF-κB signaling [99,100]. Both of these responses are 
typical hallmarks of inflammaging and inducers of 
inflammasomes.  
 
In conclusion, the decline in autophagy during aging 
creates problems in cellular housekeeping functions 
which stimulate NF-κB signaling in order to directly or 
via inflammasomes trigger an age-related pro-
inflammatory phenotype. Moreover, there are 
indications that inflammatory signaling can repress 
autophagy and thus induce this destructive interplay 
between autophagy and inflammasomes. For instance, 
tumor necrosis factor-α (TNF-α), an inflammatory 
cytokine, can induce or repress autophagy in an NF-κB-
dependent manner [101]. In the presence of NF-κB 
signaling, TNF-α activates mTOR, a major autophagy 
inhibitor, whereas in cells lacking NF-κB activation, 
TNF-α treatment stimulates the expression of Beclin 1, 
an enhancer of autophagy. Both of these responses are 
dependent on the TNF-α-induced ROS production. 
Moreover, inflammaging can also enhance 
inflammasome activation without autophagy since e.g. 
glucocorticoids, known as anti-inflammatory 
compounds secreted with aging (see above), can 
strongly induce the expression of NLRP3 in 
macrophages [102]. Thus, it seems that the elevated 
cortisol level as an anti-inflammaging response could 
increase the priming state of inflammasomes and thus 
potentiate their response sensitivity during aging.  
 
Activators of autophagy: promising drugs for 
inflammaging and related diseases 
  
As Cuervo [67] outlined, the role of autophagy is to 
"keep that old broom working" with aging. As discussed 
above, there is much evidence that caloric restriction 
can activate autophagy and also extend lifespan, 
probably via its beneficial health effects. Currently, 
there are a number of drug discovery programs aimed at 
finding safe chemicals which would be able to activate 
autophagy. There are two potential groups of 
compounds acting in this way; mTOR inhibitors 
[103,104] and AMPK activators [105,106] (Figure 1). 
mTOR is the major inhibitor of autophagy and is 
involved in aging [107,108]. Rapamycin and other 
mTOR inhibitors are either used or under investigation 
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110]. mTOR is a key protein kinase which couples 
nutritional and growth factor signaling to protein 
synthesis, transcription and critical responses in cellular 
growth, proliferation and survival. Moreover, many 
studies have reported that lifespan extension induced by 
CR is associated with the down-regulation of mTOR 
activity [108,111]. Harrison et al. [79] observed that 
rapamycin, a recognized inhibitor of mTOR, could 
extend lifespan in mice if fed late in their life. Recently, 
Anisimov et al. [112] demonstrated that the lifelong 
administration of rapamycin extended lifespan in inbred 
female mice. Moreover, rapamycin could also increase 
maximal lifespan in cancer-prone mice [113].  Cao et al. 
[114] observed that rapamycin treatment reversed the 
senescent phenotype of Hutchinson-Gilford progeria cells 
in culture by stimulating autophagy. Rapamycin 
treatment has also been reported to be able to reduce age-
related cognitive defects. Majumder et al. [115] 
demonstrated that life-long administration of rapamycin 
improved the spatial learning and memory performance 
in aging mice. Interestingly, this was associated with a 
decrease in the brain level of IL-1β but not that of TNF-α 
which could be interpreted to imply that the 
inflammasomal activity had been reduced by rapamycin 
therapy. This suggestion is in agreement with the results 
of Mawhinney et al. [116] which indicated that increased 
inflammasome activation was linked to age-related 
cognitive impairment in rats. Rapamycin, also called 
sirolimus in clinical use, has been intensively studied as 
an anti-cancer agent [109]. Rapamycin is a macrolide 
antibiotic and powerful immunosuppressant which causes 
some serious complications, e.g. lung toxicity. Currently, 
there are intensive drug discovery programs planned at 
developing rapalogues, i.e. rapamycin analogues, such as 
everolimus and temsirolimus [104]. 
 
The utilization of AMPK activators is another strategy 
with which to stimulate autophagy for therapeutic 
purposes. AMPK is an evolutionary conserved sensor 
for disturbances in cellular energy balance and a major 
inducer of autophagy [117,118]. We have recently 
reviewed the integrated signaling network through 
which AMPK regulates the aging process [119]. For 
instance, AMPK can activate autophagy by directly 
targeting ULK1 which triggers mitophagy [120]. 
Moreover, AMPK can inhibit the activity of the mTOR 
complex 1 (mTORC1), either phosphorylating the 
regulatory Raptor component or activating TSC2 which 
subsequently inhibit mTOR activity [118]. Interestingly, 
several studies have indicated that the responsiveness of 
AMPK signaling declines with aging [118] which could 
impair autophagic responses during aging. For instance, 
Reznick et al. [121] observed that physical exercise and 
AICAR, a chemical activator of AMPK, induced a 
robust increase in AMPKα2 activity in the skeletal 
muscles of young mice whereas in old rats no 
stimulation was apparent. In addition, Liu et al. [122] 
demonstrated in a mouse model that stroke induced a 
major activation of AMPK in young animals but no 
response occurred in their older counterparts. These 
studies and many other observations indicate that the 
aging process impairs the activation capacity of AMPK 
signaling and in that way, disturbs autophagic activity, 
evokes oxidative stress and triggers the activation of 
inflammasomes. Moreover, AMPK activity represses 
NF-κB signaling [123] which could suppress the 
priming of inflammasomes in young animals but this 
effect may be lost during aging. There are several 
pharmacological activators of AMPK, e.g. AICAR (5-
aminoimidazole-4-carboxamide ribonucleoside) and the 
clinically-used antidiabetic drug metformin [105]. Both 
of these compounds also have AMPK-independent 
effects. AICAR stimulates AMPK-dependent autophagy 
via ULK1 and FoxO3a [124,125]. Several natural 
products, e.g. berberine, curcumin and quercetin, have 
been reported to activate AMPK signaling [105]. 
 
In conclusion, there is substantial evidence indicating that 
autophagy is a significant regulator of innate immunity 
responses in host defence. The decline in autophagy with 
aging impairs cellular housekeeping and exposes cells to 
the risk of inflammasome activation. There is now 
convincing experimental data demonstrating that efficient 
autophagic activity can prevent the activation of 
inflammasomes and induction of inflammatory 
responses. AMPK activators and mTOR inhibitors are 
promising pharmacological agents which can effectively 
stimulate autophagic degradation. However, many of the 
present agents have toxic side effects and they can trigger 
apoptotic cell death. Moreover, it is still a matter of 
debate whether excessive autophagy can lead to 
autophagic cell death or not [126]. It seems that generally 
autophagy is a cell survival mechanism but it can be used 
for cell death e.g. during development [127] and in some 
contexts such as in tumor cell death after 
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